(Q38039489)

27 August 2017

Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection (English)

1 reference

27 August 2017

1 reference

ChEBI release 2020-05-28

1

1 reference

27 August 2017

1 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

26

1 reference

27 August 2017

10

1 reference

27 August 2017

871-882

1 reference

https://scigraph.springernature.com/pub.10.2165/11635890-000000000-00000

27 August 2017

0 references

cites work

Possible Causes of Alzheimer's Disease: Amyloid Fragments, Free Radicals, and Calcium Homeostasis

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Molecular pathways to neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Immunomodulatory drug treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

A potential role for apoptosis in neurodegeneration and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Proinflammatory cytokines, sickness behavior, and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Altered neurogenesis in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Hyperinsulinemia and risk of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Neurodegenerative disorders associated with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Increased risk of type 2 diabetes in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucose metabolism and insulin receptor signal transduction in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Insulin resistance impairs nigrostriatal dopamine function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase- dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Common pathological processes in Alzheimer disease and type 2 diabetes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Insulin-like growth factor-I, cognition and brain aging

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Insulin and the insulin receptor in experimental models of learning and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Intranasal insulin improves cognition and modulates beta-amyloid in early AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Incretin hormone mimetics and analogues in diabetes therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Exercise builds brain health: key roles of growth factor cascades and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Hope for AD with NGF gene-therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Complex genetics of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635890-000000000-00000

Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease.

21 January 2018

1 reference

12 December 2020

Synaptic plasticity and learning and memory: LTP and beyond

1 reference

12 December 2020

The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism

1 reference

12 December 2020

Models of Alzheimer's disease: cellular and molecular aspects

1 reference

12 December 2020

Insulin and cognitive function in humans: experimental data and therapeutic considerations

1 reference

12 December 2020

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

1 reference

12 December 2020

Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes

1 reference

12 December 2020

Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.

1 reference

12 December 2020

Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration.

1 reference

12 December 2020

Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain.

1 reference

12 December 2020

Entry of exendin-4 into brain is rapid but may be limited at high doses

1 reference

12 December 2020

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.

1 reference

12 December 2020

GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

1 reference

12 December 2020

Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate

1 reference

12 December 2020

Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease.

1 reference

12 December 2020

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

1 reference

12 December 2020

Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans

1 reference

12 December 2020

10.2165/11635890-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22938097

Dimensions Publication ID

27 August 2017

1013063394

0 references

Fatcat ID

release_2reyuvgor5ejpjyuby7vbps22m

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2reyuvgor5ejpjyuby7vbps22m

24 November 2022

mapped directly with Wikidata item

PubMed ID

22938097

1 reference

PubMed ID

22938097